Ingenol-3,4:5,20-diacetonide CAS: 77573-44-5

CAS NO: 77573-44-5
Chemical Name: Ingenol-3,4:5,20-diacetonide
Molecular Formula: C₂₅H₃₄O₇
Formula Weight: 446.54 g/mol
CAS Number: 77573-44-5
Description Review
Description
One prominent ingenol derivative that is gaining attention in the realm of medicinal chemistry is ingenol-3,4:5,20-diacetonide. This substance, derived from the Euphorbia peplus plant, is a synthesis of nature and scientific invention.




Popular Search Terms on Google:
Research on derivatives of ingenol,
Exploring the therapeutic potential of 77573-44-5,
Compounds found in Euphorbia peplus,
Synthesis of Ingenol-3,4:5,20-diacetonide,
Recent breakthroughs in the field of diterpenes have shown great promise in the realm of medicine.
Advancements in drug development using Ingenol,
Clinical studies of Ingenol-3,4:5,20-diacetonide
Sources of ingenol derivatives found in nature,
Groundbreaking treatments derived from extracts of Euphorbia,
The pharmacodynamics of ingenol-3,4:5,20-diacetonide.


Other products in the market that offer similar features:
Other ingenol derivatives and diterpene-based compounds, especially those utilized in oncological and dermatological therapies, are competitors to ingenol-3,4:5,20-diacetonide.


Possible Health Benefits and Effects:
Ingenol-3,4:5,20-diacetonide has great potential as a cancer treatment and in the treatment of skin problems, among other ailments. Because of its one-of-a-kind characteristics, it might have revolutionary uses in the medical field.



Explanation of How It Works:
A complicated process is responsible for the operation of this chemical, which allows it to connect with cellular signaling pathways. Oncology is very interested in how it affects cell death pathways, especially in cancer cells.



Safety and Effects on Other People:
While ingenol-3,4:5,20-diacetonide has great promise, its safety profile demands careful consideration. It is crucial to thoroughly evaluate the possibility of adverse effects and the danger of toxicity, particularly with extended use.


Information on dosing:
Information on the appropriate dosage of ingenol-3,4:5,20-diacetonide is contingent upon the particular use and the features of the patient. Dosing is best based on clinical recommendations and research.


Important considerations:
People who suffer from certain medical disorders, especially those involving the liver and kidneys, may have to stay away from this substance. Its combination with other drugs is another cause for concern.


In summary:
Ingenol-3,4:5,20-diacetonide is proof that molecules from nature are still being studied in modern medicine. Its future seems bright, thanks to continuing research and its potential to cure a variety of illnesses, but only if its intricacies and safety implications are well understood.


Additional Questions:

What are the main applications of Ingenol-3,4:5,20-diacetonide?
Its potential for treating certain skin problems and cancer treatments is the main reason for its study.

How is Ingenol-3,4:5,20-diacetonide made?
The ingenol compound found in the Euphorbia peplus plant is chemically modified to produce it.


What are the recognized adverse reactions that might occur while using ingenol-3,4:5,20-diacetonide?
As with many substances, negative effects may occur, and its safety is being studied in clinical settings.



Is there a possibility of drug interactions with Ingenol-3,4:5,20-diacetonide?
Considerable research effort is devoted to identifying potential drug interactions; therefore, it is critical to seek the advice of healthcare professionals.

  1. Ingenol-3,4:5,20-diacetonide research,
  2. Euphorbia peplus medicinal uses,
  3. Diterpene compounds in pharmacology,
  4. Ingenol derivatives,
  5. Acetonide group in medicinal chemistry,
  6. Therapeutic potential of ingenol,
  7. Ingenol stability enhancements,
  8. Solubility of ingenol derivatives,
  9. Ingenol in cancer treatment,
  10. Biological activities of ingenol-3,4:5,20-diacetonide,
  11. Ingenol-3,4:5,20-diacetonide structure,
  12. Petty spurge extract benefits,
  13. Ingenol-based drug development,
  14. Medicinal properties of Euphorbia peplus,
  15. Ingenol chemical modifications,
  16. Reactivity of ingenol compounds,
  17. Ingenol in clinical research,
  18. Natural diterpenes in medicine,
  19. Ingenol pharmacokinetics,
  20. Ingenol-3,4:5,20-diacetonide solubility studies.
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code